GlassScriptPhysician profile
Juhee N Mian
NPI 1780003772
$2,276.69
in general payments reported to CMS, 2019-2025
19 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.22 · 2020: $38.46 · 2021: $288 · 2022: $272 · 2023: $579 · 2024: $376 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Consulting Fee: $150 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.99 |
| Consulting Fee | $150.00 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $571.43 | 2021-2025 | Wakix |
| Inspire Medical Systems, INC. | $504.95 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $433.09 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $412.56 | 2021-2025 | Xywav |
| Abbvie INC. | $72.78 | 2021 | |
| Idorsia Pharmaceuticals US INC | $36.72 | 2023 | Quviviq |
| Amarin Pharma, INC. | $33.13 | 2021 | |
| Amgen INC. | $27.95 | 2019-2021 | |
| Novo Nordisk INC | $27.36 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $26.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $25.20 | 2021 | |
| Lilly USA, LLC | $15.70 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $15.25 | 2021 | |
| Radius Health, INC. | $13.92 | 2021 | |
| Esperion Therapeutics, INC. | $12.78 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $12.11 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.82 | 2021 | |
| Eisai INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juhee Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.